oncliveMay 151 min read

FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder Cancer

The FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.

source

Reporting by onclive. The original article may no longer be reachable at its published URL.

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

oncliveMay 151 min read

The FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.

source

Reporting by onclive. The original article may no longer be reachable at its published URL.